Szadkowski Marta, Iaccarino Ingram, Heinimann Karl, Marra Giancarlo, Jiricny Josef
Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
Cancer Res. 2005 Jun 1;65(11):4525-9. doi: 10.1158/0008-5472.CAN-05-0080.
Mutations in mismatch repair (MMR) genes predispose to hereditary nonpolyposis colon cancer. Those leading to truncated proteins bring about a MMR defect, but phenotypes of missense mutations are harder to predict especially if they do not affect conserved residues. Several systems capable of predicting the phenotypes of MMR missense mutations were described. We deployed one of these to study the MMR defect in MT1 cells, which carry mutations in both alleles of the hMSH6 gene. In one, an A-->T transversion brings about an Asp(1213)Val amino acid change in the highly conserved ATP binding site, whereas the other carries a G-->A transition, which brings about a Val(1260)Ile change at a nonconserved site. The hMSH2/hMSH6 (hMutS alpha) heterodimers carrying these mutations were expressed in the baculovirus system and tested in in vitro MMR assays. As anticipated, the Asp(1213)Val mutation inactivated MMR by disabling the variant hMutS alpha from translocating along the DNA. In contrast, the recombinant Val(1260)Ile variant displayed wild-type activity. Interestingly, partial proteolytic analysis showed that this heterodimer was absent from MT1 extracts, although both hMSH6 alleles in MT1 cells could be shown to be transcribed with an efficiency similar to each other and to that seen in control cells. The MMR defect in MT1 cells is thus the compound result of one mutation that inactivates the ATPase function of hMutS alpha and a second mutation that apparently destabilizes the Val(1260)Ile hMSH6 protein in human cells in vivo.
错配修复(MMR)基因的突变易导致遗传性非息肉病性结直肠癌。那些导致截短蛋白的突变会引起MMR缺陷,但错义突变的表型更难预测,尤其是当它们不影响保守残基时。已经描述了几种能够预测MMR错义突变表型的系统。我们采用其中一种系统来研究MT1细胞中的MMR缺陷,MT1细胞的hMSH6基因的两个等位基因都发生了突变。在其中一个突变中,A→T颠换导致高度保守的ATP结合位点发生天冬氨酸(1213)缬氨酸氨基酸变化,而另一个突变携带G→A转换,导致在一个非保守位点发生缬氨酸(1260)异亮氨酸变化。携带这些突变的hMSH2/hMSH6(hMutSα)异二聚体在杆状病毒系统中表达,并在体外MMR测定中进行测试。正如预期的那样,天冬氨酸(1213)缬氨酸突变通过使变异的hMutSα无法沿DNA移位而使MMR失活。相反,重组的缬氨酸(1260)异亮氨酸变异体显示出野生型活性。有趣的是,部分蛋白水解分析表明,MT1提取物中不存在这种异二聚体,尽管MT1细胞中的两个hMSH6等位基因都能以彼此相似且与对照细胞中相似的效率转录。因此,MT1细胞中的MMR缺陷是一个使hMutSα的ATP酶功能失活的突变和另一个明显使体内人类细胞中的缬氨酸(1260)异亮氨酸hMSH6蛋白不稳定的突变的复合结果。